Pfizer Says Wyeth Acquisition, Economic Factors Drove Decision to Scuttle Mission Bay Deal

The decision, made less than a year after Pfizer penned the deal, reflects a study of its space needs in light of its planned $68 billion acquisition of Wyeth, as well as simple economics. The departure is also a setback for Mission Bay and the Bay Area's lab space market.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.